AB InBev Reports First Quarter 2026 Results May 5, 2026 Solid top- and bottom-line performance: Revenue up by 5.8%, Beer volume growth of 1.2% and a 20.8% Underlying EPS increase
Prothena to Report First Quarter 2026 Financial Results on May 7 April 30, 2026 Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2026 financial results on Thursday, May 7, 2026, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be [...]
Estithmar Holding Reports 97% Surge YoY in Q1 2026 in Net Profit to QAR 333 Mn April 29, 2026 Strong performance reflects sustained upward momentum driven by international expansion and operational efficiency Digital transformation initiatives in automation and artificial intelligence enhanced productivity, governance, and cost optimization
Allegion (NYSE: ALLE) Reports Q1-2026 Financial Results April 28, 2026 High-Single Digit Revenue Growth for the Enterprise; Affirming FY-2026 Organic Revenue Outlook Quarterly Financial Highlights (All comparisons are year-over-year, unless otherwise noted) Net earnings per share (EPS) of $1.59, down 7.0% compared with $1.71; Adjusted EPS of $1.80, down 3.2% compared with $1.86 Revenues of $1,033.6 million, up 9.7% on a reported basis and up 2.6% on an organic basis Operating margin of 18.9%, compared with 20.9%; Adjusted operating margin of 21.2%, compared with 22.7%
Janus Henderson to Report First Quarter 2026 Results April 24, 2026 Janus Henderson Group plc (NYSE: JHG) (“Janus Henderson” or the “Company”) will announce its first quarter 2026 results after market close on Friday, May 8, 2026. While the previously announced take-private transaction with Trian Fund Management, L.P. and its affiliated funds, and General Catalyst Group Management, LLC and its affiliated funds remains pending, the Company [...]
Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights April 23, 2026 Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation
REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements April 23, 2026 Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024); Group net profits of €250.9 million (€211.1 million in 2024). Approval of the proposal to distribute a dividend of €1.35 per share. Approval of the plan for the purchase and/or disposal of treasury shares.
Bureau Veritas: A Steady Organic Revenue Growth in the First Quarter 2026 April 22, 2026 An evolving macro-environment and a transitioning portfolio mix; Updated 2026 outlook
Arm Announces Earnings Release Date for Fourth Quarter Fiscal Year Ended 2026 April 8, 2026 Arm Holdings plc (NASDAQ: ARM) will report financial results for the fourth quarter of fiscal year 2026 on Wednesday, May 6, 2026, after market close. The company will host a conference call via audio webcast at 14:00 Pacific Time (17:00 Eastern Time / 22:00 British Summer Time) to review its financial results and business outlook. [...]
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth March 27, 2026 Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD [...]